Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1994 Jul 2;309(6946):4–5. doi: 10.1136/bmj.309.6946.4

Bone marrow transplants from peripheral blood.

T L Holyoake, I M Franklin
PMCID: PMC2542633  PMID: 7913849

Full text

PDF
4

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage J. O. Bone marrow transplantation. N Engl J Med. 1994 Mar 24;330(12):827–838. doi: 10.1056/NEJM199403243301206. [DOI] [PubMed] [Google Scholar]
  2. Bender J. G., Unverzagt K. L., Walker D. E., Lee W., Van Epps D. E., Smith D. H., Stewart C. C., To L. B. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood. 1991 Jun 15;77(12):2591–2596. [PubMed] [Google Scholar]
  3. Blaese R. M., Culver K. W., Chang L., Anderson W. F., Mullen C., Nienhuis A., Carter C., Dunbar C., Leitman S., Berger M. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Hum Gene Ther. 1993 Aug;4(4):521–527. doi: 10.1089/hum.1993.4.4-521. [DOI] [PubMed] [Google Scholar]
  4. Bregni M., Magni M., Siena S., Di Nicola M., Bonadonna G., Gianni A. M. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood. 1992 Sep 15;80(6):1418–1422. [PubMed] [Google Scholar]
  5. Canellos G. P., Demetri G. D. Myelosuppression and "conventional" chemotherapy: what price, what benefit? J Clin Oncol. 1993 Jan;11(1):1–2. doi: 10.1200/JCO.1993.11.1.1. [DOI] [PubMed] [Google Scholar]
  6. Cassel A., Cottler-Fox M., Doren S., Dunbar C. E. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol. 1993 Apr;21(4):585–591. [PubMed] [Google Scholar]
  7. Civin C. I., Strauss L. C., Brovall C., Fackler M. J., Schwartz J. F., Shaper J. H. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol. 1984 Jul;133(1):157–165. [PubMed] [Google Scholar]
  8. Dreger P., Suttorp M., Haferlach T., Löffler H., Schmitz N., Schroyens W. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood. 1993 Mar 1;81(5):1404–1407. [PubMed] [Google Scholar]
  9. Hénon P. R. Peripheral blood stem cell transplantations: past, present and future. Stem Cells. 1993 May;11(3):154–172. doi: 10.1002/stem.5530110302. [DOI] [PubMed] [Google Scholar]
  10. Kessinger A., Armitage J. O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood. 1991 Jan 15;77(2):211–213. [PubMed] [Google Scholar]
  11. Lobo F., Kessinger A., Landmark J. D., Smith D. M., Weisenburger D. D., Wigton R. S., Armitage J. O. Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten marrow recovery following myeloablative therapy. Bone Marrow Transplant. 1991 Nov;8(5):389–392. [PubMed] [Google Scholar]
  12. Richman C. M., Weiner R. S., Yankee R. A. Increase in circulating stem cells following chemotherapy in man. Blood. 1976 Jun;47(6):1031–1039. [PubMed] [Google Scholar]
  13. Russell N. H., Hunter A., Rogers S., Hanley J., Anderson D. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet. 1993 Jun 5;341(8858):1482–1482. doi: 10.1016/0140-6736(93)90929-b. [DOI] [PubMed] [Google Scholar]
  14. Siena S., Bregni M., Brando B., Ravagnani F., Bonadonna G., Gianni A. M. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989 Nov 1;74(6):1905–1914. [PubMed] [Google Scholar]
  15. Tepler I., Cannistra S. A., Frei E., 3rd, Gonin R., Anderson K. C., Demetri G., Niloff J., Goodman H., Muntz H., Muto M. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol. 1993 Aug;11(8):1583–1591. doi: 10.1200/JCO.1993.11.8.1583. [DOI] [PubMed] [Google Scholar]
  16. To L. B., Haylock D. N., Kimber R. J., Juttner C. A. High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol. 1984 Nov;58(3):399–410. doi: 10.1111/j.1365-2141.1984.tb03987.x. [DOI] [PubMed] [Google Scholar]
  17. Wunder E., Sovalat H., Fritsch G., Silvestri F., Henon P., Serke S. Report on the European Workshop on Peripheral Blood Stem Cell Determination and Standardization--Mulhouse, France, February 6-8 and 14-15, 1992. J Hematother. 1992 Summer;1(2):131–142. doi: 10.1089/scd.1.1992.1.131. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES